ArticleQuantitative imaging in medicine and surgery2025
Clinical research on echocardiographic screening for pulmonary hypertension: TRV >2.8 m/s and mPAP >20 mmHg.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In 2022, the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) revised the diagnostic criteria for pulmonary hypertension (PH) from mean pulmonary arterial pressure (mPAP) ≥25 mmHg to >20 mmHg. However, the echocardiographic standards [the tricuspid regurgitation velocity (TRV) >2.8 m/s] have not been updated. This study aims to optimize the reference value of TRV, and evaluate the discriminatory efficacy of TRV in pulmonary artery pressure grading. Methods: Patients suspected of having PH underwent both ultrasound (US) and right heart catheterization (RHC) examinations. The TRV and tricuspid regurgitant pressure gradient (ΔPTR) were measured via US. Right atrial pressure (RAP) was estimated via US by related parameters of the inferior vena cava. Subsequently, the systolic pulmonary artery pressure measured by ultrasound (US-sPAP) was equivalent to RAP + ΔPTR. RHC recorded the systolic pulmonary artery pressure (RHC-sPAP) and mean pulmonary artery pressure (RHC-mPAP). The reference standards for TRV and US-sPAP were established using RHC-mPAP >20 mmHg or RHC-mPAP ≥25 mmHg as diagnostic criteria for PH, respectively. Patients were classified into mild (20 mmHg < mPAP ≤30 mmHg), moderate (30 mmHg < mPAP ≤40 mmHg), and severe (mPAP >40 mmHg) and the reference criteria for TRV and US-sPAP were then determined accordingly. Results: A total of 257 patients were included in this study, comprising 218 patients with mPAP >20 mmHg and 192 patients with mPAP ≥25 mmHg. There was no statistically significant difference between US-sPAP and RHC-sPAP (P=0.969), and the correlation was significant (r=0.793, P<0.001). Bland Altman analysis showed high consistency (intraclass correlation coefficient =0.762). When mPAP >20 mmHg was used as the threshold for diagnosing PH, the optimal cut-off values for US-sPAP, TRV, and RHC-sPAP were 37 mmHg, 2.9 m/s, and 41 mmHg, respectively [areas under the curve (AUCs) 0.926, 0.936, 0.981, accuracies 89.9%, 89.5%, 90.3%]. The cut-off values for distinguishing mild/moderate elevation of mPAP were 60 mmHg, 3.7 m/s, and 57 mmHg, respectively (AUC 0.903, 0.900, 0.988, accuracy 81.3%, 80.9%, 94.2%). The cut-off values for distinguishing moderate/severe elevation were 68 mmHg, 4.0 m/s, and 72 mmHg (AUC 0.881, 0.882, 0.971, accuracy 81.3%, 82.9%, 91.1%), respectively. When mPAP ≥25 mmHg was used as the diagnostic threshold for PH, the AUCs for US-sPAP, TRV, and RHC-sPAP were 0.931, 0.933, and 0.990, respectively, with cut-off values of 45 mmHg, 3.4 m/s, and 43 mmHg, and accuracies of 86.8%, 80.5%, and 96.5%. Conclusions: Utilizing a TRV threshold of >2.8 m/s for echocardiographic assessment aligns more closely with the 2022 guidelines (mPAP >20 mmHg) but demonstrates poor correlation with the 2015 guidelines (mPAP ≥25 mmHg). Additionally, US-sPAP ≥37 mmHg can serve as a reliable criterion for assessing PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.